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Available online 24 October 2016AbstractObjective: There has been no prospective study that examined intramuscular injection of high-dose vitamin D in Korean adults. The aim of this
study was to assess the efficacy and safety of high-dose vitamin D3 after intramuscular injection in Korean adults with vitamin D deficiency.
Method: This study was a 24-week, prospective, multicenter, randomized, double-blind, placebo-controlled trial. A total of 84 subjects 19 and
<65 years of age were randomly allocated to either the vitamin D3 or placebo group in a 2:1 ratio. After randomization, a single injection of plain
vitamin D3 200,000 IU or placebo was intramuscularly administered. If serum 25-hydroxyvitamin D (25[OH]D) concentrations were <30 ng/mL
on week 12 or thereafter, a repeat injection was administered.
Results: After a single intramuscular injection of vitamin D3 to adults with vitamin D deficiency, the proportion of subjects with serum 25(OH)D
concentrations 30 ng/mL within 12 weeks was 46.4% in the vitamin D3 group and 3.6% in the placebo group (p < 0.0001). The proportion of
subjects with serum 25(OH)D concentrations 30 ng/mL within 24 weeks was 73.2% in the vitamin D3 group and 3.6% in the placebo group
(p < 0.0001). Mean change in serum 25(OH)D concentrations at weeks 12 and 24 after vitamin D3 injection was 12.8 ± 8.1 and 21.5 ± 8.1 ng/
mL, respectively, in the vitamin D3 group, with no significant changes in the placebo group. Serum parathyroid hormone concentrations showed
a significant decrease in the vitamin D3 group but no change in the placebo group.
Conclusion: Intramuscular injection of vitamin D3 200,000 IU was superior to placebo in terms of its impact on serum 25(OH)D concentrations,
and is considered to be safe and effective in Korean adults with vitamin D deficiency.
© 2016 The Korean Society of Osteoporosis. Publishing services by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Vitamin D is essential in bone and mineral metabolism.
Accordingly, low vitamin D status is associated with osteo-
porosis and fractures. Severe deficiency of vitamin D can lead
to bone mineralization defects, such as rickets in children and* Corresponding author. Department of Internal Medicine, Yonsei University
College of Medicine, Seoul, South Korea.
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(http://creativecommons.org/licenses/by-nc-nd/4.0/).osteomalacia in adults [1,2]. Recently, it has been suggested
that vitamin D also has important roles in other tissues besides
the skeletal system with its deficiency closely associated with
an increased risk of several non-skeletal disorders, such as
cancers, infection, autoimmune diseases, cardiovascular dis-
eases, and diabetes mellitus [3e8]. Despite growing awareness
of the multiple health benefits of vitamin D, vitamin D defi-
ciency has become a major health concern in modern society.
As more people spend a majority of their time indoors, sun-
light exposure can be inadequate for cutaneous production of
vitamin D. Epidemiological studies have indicated a highlsevier B.V. This is an open access article under the CC BY-NC-ND license
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Asian countries [9e12]. When serum 25-hydroxyvitamin D
(25[OH]D) level of 30 ng/mL was adopted as the cut-off
value, the prevalence of vitamin D insufficiency in Korean
general population was 86.8% in men and 93.3% in women,
which was higher than that of the United States and Canada
[13].
The increasing prevalence of limited exposure to sunlight is
increasing the importance of dietary sources of vitamin D in
maintaining people's vitamin D status in modern society. Fatty
fish, egg yolks, and mushrooms are some of the few natural
foods that contain vitamin D. In western countries, vitamin D
is supplied in the diet of many people by fortifying foods. In
the 1930s, a milk fortification program was implemented in
the United States to combat rickets [14]. Other vitamin D
fortified food products in western countries are breakfast ce-
reals, orange juice, yogurt, and margarine. However, food
fortification is uncommon in Asian countries.
A more realistic and easier way to get enough vitamin D is
supplementation through either oral or intramuscular route.
High-dose vitamin D administered intramuscularly has been
effectively used to achieve and maintain individual's sufficient
vitamin D status. However, there has been no prospective
study of intramuscular injection of high-dose plain vitamin D
in Korean adults. This prospective, multicenter, randomized,
double-blind, placebo-controlled study was conducted to
compare 200,000 IU of vitamin D3 with placebo in terms of
efficacy and safety for 24 weeks after intramuscular injection
in Korean adults with vitamin D deficiency.
2. Subjects and methods2.1. Study subjectsThe study subjects were recruited at three different in-
stitutions (Yonsei University Severance Hospital, Ajou Uni-
versity Hospital, Dongguk University Ilsan Hospital) in South
Korea. After the screening test, male or female subjects with
serum 25(OH)D concentration <20 ng/mL who were between
19 and 65 years of age, were enrolled in this study. Reasons
for exclusion included history of hypersensitivity reactions to
cholecalciferol component; renal disorder (serum creatinine
>1.25 upper limit of normal [ULN]); hypercalcemia (serum
calcium >10.5 mg/dL); hypercalciuria (urine calcium >4 mg/
kg/day or urine calcium [mg/dL]/creatinine [mg/dL] ratio
>0.2); suspected calcium stone with clinical findings;
sarcoidosis; pseudohypoparathyroidism; malignancies (a pa-
tient who was judged to have been cured as 5 years had passed
since treatment was able to participate in the study); clinically
significant cardiovascular and pulmonary function disorder
based on the judgment of the investigator; laboratory test
findings as follows: platelet <100,000/mm3, white blood cell
(WBC) < 3000/mm3, absolute neutrophil count <1500/mm3,
albumin <3.0 g/dL, aspartate aminotransferase (AST) or
alanine aminotransferase (ALT) >1.5 ULN; treatment with
phenytoin or barbiturates within 5 days prior to the investi-
gational product injection; treatment with thiazide diureticswithin 3 days prior to the investigational product injection;
treatment with glucocorticoids, cholestyramine, colestipol, or
cardiac glycosides within 1 day prior to the investigational
product injection; requirement of vitamin D supplements
during the study; use of tanning booths during the study;
pregnant and lactating female; women of childbearing poten-
tial who do not use adequate contraception; and individuals
deemed inappropriate for study participation by the investi-
gator, currently participating in another clinical trial or having
had the last dose of another investigational product within the
past 4 weeks. A total of 84 subjects (56 in the vitamin D3
group and 28 in the placebo group, planned to be assigned in a
2:1 ratio) were enrolled (Fig. 1). Subjects were to be stratified
by serum 25(OH)D concentrations (<10 ng/mL or 10e20 ng/
mL) in a 1:1 ratio. This study was carried out in accordance
with principles of Korea Good Clinical Practice, International
Conference on Harmonization-Good Clinical Practice,
Declaration of Helsinki, and local laws and applicable regu-
lations. This study was approved by the Institutional Review
Board (IRB) at each institution (IRB No. 4-2014-0377, Yonsei
University Severance Hospital; IRB NO. AJIRB-MED-CT3-
13-397, Ajou University Hospital; IBR No. 2014-16, Dong-
guk University Ilsan Hospital). All subjects provided their
written informed consent for the study after they were pro-
vided a detailed description of the experimental procedures
and informed that they could withdraw from the study at any
time.2.2. Study designThe 24-week, prospective, multicenter, randomized,
double-blind, placebo-controlled clinical trial was conducted
between from November 2014 to August 2015 at the three
aforementioned institutions in Korea. Following the screening
visit, at which inclusion and exclusion criteria were assessed,
subjects were randomly assigned to either the vitamin D3
group or the placebo group in a 2:1 ratio. Vitamin D3 B.O.N
was manufactured by Haupt Pharma Livron (France) as a
fragrance free, slightly yellow, transparent injectable solution
(200,000 IU [5 mg] as cholecalciferol) contained in a colorless
and transparent ampoule. All participants, investigators,
pharmacists, and study personnel were blinded to treatment
allocation. This study was comprised of period 1 and 2
(Fig. 2). Period 1 was the duration of time from baseline to the
end of week 12. During this time, the first injection of vitamin
D3 and tests for primary efficacy assessment were carried out.
Period 2 was the duration of time from week 13 to the end of
week 24. During this time, subjects who had serum 25(OH)D
concentrations <30 ng/mL at the time of week 12 or thereafter
received a repeat single injection of the investigational product
and subjects 30 ng/mL were followed up to week 24 without
an additional injection. The enrolled subjects were scheduled
to visit 9 times (at week 0, 2, 4, 6, 8, 12, 14, 18, and 24) during
the trial and their clinical information and trial data were
collected during individual interviews conducted by a well-
trained interviewer. All subjects underwent a through medi-
cal history review and a physical examination. During the
Fig. 2. Study design.
Fig. 1. Randomization scheme and subject disposition.
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additional vitamin D supplements. Exposure to direct sunlight
for 10 h or longer per week, trips to countries with more
sunshine than Korea during the study, sunbath, or long hoursor working under direct sunlight were also prohibited. Usual
diets were to be maintained and diets containing vitamin D
that could affect the efficacy of the investigational product
(cod liver oil, cooked salmon and mackerel, sardine, etc.) were
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ing the study to the investigators, and had to discuss in
advance if he/she had to receive additional drugs or change
type or dosage of drugs. If a drug administered without the
judgment of the principal investigator was expected to affect
efficacy and safety assessments for this study, the relevant
subject was to be withdrawn.2.3. EfficacyThe primary efficacy endpoint was proportion of subjects
with improved serum 25(OH)D concentrations 30 ng/mL
within 12 weeks after the investigational product injection.
The secondary efficacy endpoints were proportion of subjects
with improved serum 25(OH)D concentrations 30 ng/mL at
week 4, 6, 8, 12, 18, and 24; proportion of subjects with
improved serum 25(OH)D concentrations 20 ng/mL at
weeks 4, 6, 8, 12, 18, and 24; and change in serum 25(OH)D
concentrations at weeks 4, 6, 8, 12, 18, and 24 after the
investigational product injection from baseline. Exploratory
endpoints were mean change in maximum serum 25(OH)D
concentration (DCmax), mean time to Cmax (Tmax), and area
under the curve (AUC)12weeks for serum 25(OH)D concentra-
tions after a single injection of the investigational product, and
change in serum parathyroid hormone (PTH) concentrations at
week 4, 8, 12, 18, and 24 after the investigational product
injection.2.4. SafetySafety was assessed by adverse events (AEs) reported by
subjects, physical examination, electrocardiography, and lab-
oratory parameters. During the trial, all subjects were asked to
report potential AEs. Vital signs of each subject including
systolic and diastolic blood pressure and pulse rate were
measured at every visit. Clinical evaluations and laboratory
measurements, including serum chemistry and hematology
were performed at selected visits. Proportion of subjects with
increased serum 25(OH)D concentrations 60, 100, and
150 ng/mL after vitamin D3 injection was determined at
week 4, 6, 8, 12, 18, and 24. Serious AEs (SAEs) were
immediately reported to the Kwangdong Pharmaceutical Co.,
Ltd within 24 h after recognition regardless of the in-
vestigator's assessment of a causal relationship to study drug.2.5. Laboratory measurementsSerum 25(OH)D and intact PTH were analyzed at the
central laboratory. Serum 25(OH)D concentrations were
measured by electrochemiluminescence immunoassay
(ECLIA) (Roche Diagnostics, Mannheim, Germany). The
intra- and interassay coefficient of variation (CV) of 25(OH)D
measurements was 2.2e6.9 and 3.4e13.1%, respectively.
Intact PTH concentrations were also measured by ECLIA
(Roche Diagnostics, Mannheim, Germany). The intra- and
interassay CV of intact PTH measurements was 1.1e2.0 and
2.8e3.4%, respectively. Clinical chemistry test (glucose,calcium, phosphorus, blood urea nitrogen, creatinine, total
bilirubin, AST, ALT, gamma glutamyl transpeptidase, alkaline
phosphatase, total protein, sodium, potassium, total choles-
terol, albumin, and insulin), hematologic test (hemoglobin,
hematocrit, platelet count, WBC count with differential count,
and hemoglobin A1c), and urinalysis (pH, protein, glucose,
blood, ketones, urobilinogen, bilirubin, nitrite, leukocytes)
were assessed at each site.2.6. Statistical analysesEfficacy was analyzed in the full analysis set (FAS) popu-
lation defined as subjects who had at least one assessment of
efficacy after randomization, and in the per-protocol set (PPS)
defined as the FAS subjects who completed the study without
major protocol deviations. Safety was analyzed in the safety
set defined as randomized subjects who received at least one
injection of the study drug. All statistical tests were to be
performed as two-sided tests at a significance level of 0.05 in
this study, in principle. Number of subjects, mean ± standard
deviation (SD) or standard error (SE), median, minimum, and
maximum were presented for continuous variables and fre-
quency and percentage were presented for categorical vari-
ables. Continuous variables were tested for normality. Two-
sample t-test, paired t-test, Wilcoxon rank sum test, or Wil-
coxon signed rank test was performed depending on whether
normality assumption was met. Categorical variables were
analyzed using Pearson's chi-square test or Fisher's exact test
depending on whether 80% had an expected value of 5.
Calculations and statistical analyses were performed using
SAS 9.3 (SAS Institute, Cary, NC, USA).
3. Results
Out of 115 subjects who were screened, 84 subjects were
enrolled, with 56 randomized to the vitamin D3 group and 28
to the placebo group. Among those, 4 subjects dropped out
due to withdrawal of informed consent (2 subjects in the
vitamin D3 group and 2 subjects in the placebo group) and the
remaining 80 subjects (54 subjects in the vitamin D3 group and
26 subjects in the placebo group) completed the study. All of
the 84 randomized subjects were included in the safety set and
the FAS. Among those, a total of 7 subjects were excluded
from the PPS; they comprised 1 subject in the placebo group
with missing primary efficacy assessment at week 12 visit, 2
subjects in the placebo group with administration of prohibited
concomitant medications, and 4 subjects in the vitamin D3
group with other major protocol violation. The remaining 77
subjects were included in the PPS (Fig. 1).3.1. Demographic and other baseline characteristics of
subjectsMean age of subjects was 37.4 ± 10.4 years in the vitamin
D3 group and 36.2 ± 10.6 years in the placebo group. Mean
body mass index (BMI) was 22.3 ± 2.6 kg/m2 and
21.9 ± 2.0 kg/m2 in the vitamin D3 and the placebo group,
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in demographic information and other baseline characteristics
of subjects between the groups (Table 1).3.2. EfficacyThe proportion of subjects with improved serum 25(OH)D
concentrations 30 ng/mL within 12 weeks after the investi-
gational product injection, the primary efficacy endpoint in this
study, was 46.4% (26/56) in the vitamin D3 group and 3.6% (1/
28) in the placebo group (p < 0.0001), and the proportion of
those 20 ng/mL within 12 weeks after injection was 92.9%
(52/56) in the vitamin D3 group and 10.7% (3/28) in the pla-
cebo group (p < 0.0001) (Fig. 3). After week 12, the investi-
gational product repeat injection rate in the vitamin D3 group
was 76.8% (43/56), 7.1% (4/56), and 3.6% (2/56) at week 14,
18, and 20, respectively, resulting in a total repeat injection rate
of 87.5% (49/56). Meanwhile, in the placebo group, all subjects
except one who had been prematurely withdrawn received the
repeat injection of the investigational product, resulting in a
total repeat injection rate of 96.4% (27/28).
Concerning the secondary efficacy endpoints, the propor-
tion of subjects with serum 25(OH)D concentrations 30 ng/
mL at week 4, 6, 8, 12, 18, and 24 after the investigational
product injection was 25.0% (14/56), 26.8% (15/56), 28.6%
(16/56), 21.4% (12/56), 60.7% (34/56), and 62.5% (35/56),
respectively, in the vitamin D3 group. Additionally, the pro-
portion of subjects with improved 25(OH)D concentrations
30 ng/mL within each time point was 28.6% (16/56), 33.9%
(19/56), 44.6% (25/56), 46.4% (26/56), 71.4% (40/56), and
73.2% (41/56) within week 4, 6, 8, 12, 18, and 24, respectively
(Table 2). The proportion of subjects with serum 25(OH)D
concentrations 20 ng/mL at week 4, 6, 8, 12, 18, and 24 after
the investigational product injection was 73.2% (41/56),
83.9% (47/56), 75.0% (42/56), 64.3% (36/56), 94.6% (53/56),
and 96.4% (54/56), respectively, in the vitamin D3 group.
Additionally, the proportion of subjects with improved serumTable 1
Demographic and other baseline demographic characteristics of the study
participants.
Variable Vitamin D3 group
(N ¼ 56)
Placebo group
(N ¼ 28)
p
Age (years) 37.4 ± 10.4 36.2 ± 10.6 0.6079b
Gender (M/F) 9/47 3/25 0.7426c
Height (cm) 163.2 ± 6.3 163.3 ± 6.2 0.7609b
Body weight (kg) 59.5 ± 8.0 58.5 ± 7.5 0.6135a
BMI (kg/m2) 22.3 ± 2.6 21.9 ± 2.0 0.4662a
Serum 25(OH)D (ng/mL) 10.2 ± 3.9 10.3 ± 3.6 0.8736a
10e20 at baseline 13.4 ± 2.3 13.1 ± 2.7 0.6694b
<10 at baseline 7.0 ± 2.1 7.5 ± 1.5 0.3527a
Serum calcium (mg/dL) 9.2 ± 0.3 9.2 ± 0.3 0.6401a
Serum phosphorus (mg/dL) 3.4 ± 0.5 3.6 ± 0.4 0.2082a
Hemoglobin A1C (%) 5.4 ± 0.3 5.3 ± 0.3 0.2927b
Data are mean ± SD, except gender.
BMI, body mass index; 25(OH)D, 25-hydroxyvitamin D.
a Two-sample t-test.
b Wilcoxon rank sum test.
c Fisher's exact test.25(OH)D concentrations 20 ng/mL within each time point
was 78.6% (44/56), 91.1% (51/56), 92.9% (52/56), 92.9% (52/
56), 98.2% (55/56), and 100.0% (56/56) within week 4, 6, 8,
12, 18, and 24, respectively (Table 2). The proportions of
subjects with serum 25(OH)D concentrations 30 or 20 ng/
mL within each time point depending on repeat injection of
the investigational product were shown in Supplemental Table
1. At baseline, mean serum 25(OH)D concentration was
10.2 ± 3.9 ng/mL in the vitamin D3 group and 10.3 ± 3.6 ng/
mL in the placebo group. Mean serum 25(OH)D concentration
up to week 8 following a single injection of the vitamin D3
200,000 IU was 25.6 ng/mL, which slightly declined at week
12, and then showed an additional increase following the
repeat injection, resulting in a mean serum 25(OH)D con-
centration of 31.7 ng/mL at week 24. In the placebo group,
serum 25(OH)D concentrations at each time point showed
almost no change. Changes in mean serum 25(OH)D con-
centrations over 24-week treatment period depending on
repeat injection are shown in Fig. 4.
In an exploratory analysis, DCmax from baseline after a
single injection of the vitamin D3 200,000 IU was
21.2 ± 7.2 ng/mL and Tmax was 55.2 ± 25.5 days. In addition,
AUC12weeks after a single injection of the vitamin D3 200,000
IU was 1064.7 ± 435.5 ng$day/mL (Table 3). Mean change in
serum PTH concentrations at weeks 4, 8, 12, 18, and 24 after
the investigational product injection in the vitamin D3 group
was 1.8 ± 13.5, 4.1 ± 10.9, 0.6 ± 24.0, 6.0 ± 9.5, and
3.3 ± 10.9 pg/mL, respectively, which indicated a statistically
significant intra-group decrease (p ¼ 0.0009). In the placebo
group, however, the respective mean concentration change was
1.2 ± 14.0, 1.6 ± 14.8, 2.1 ± 14.6, 5.2 ± 12.3, and
1.0 ± 16.0 pg/mL, which showed no statistically significant
intra-group change (p ¼ 0.1084). There was a statistically
significant inter-group difference at week 8, 18, and 24 (week
8: p ¼ 0.0045, week 18: p ¼ 0.0237, week 24: p ¼ 0.0319).3.3. SafetyDuring the study, the incidence rate of treatment emergent
AEs was 57.1% in the vitamin D3 group and 67.9% in the
placebo group (Supplemental Table 2A). Of the total 62 AEs
in the vitamin D3 group, 59 events (95.2%) were mild and 3
events (4.8%) were moderate. Of the total 32 AEs in the
placebo group, 30 events (93.8%) were mild and 2 events
(6.3%) were moderate. Neither group had severe AEs. Among
the mild AEs, 9 events (14.5%) in the vitamin D3 group and 3
events (9.4%) in the placebo group were adverse drug re-
actions (Supplemental Table 2B). The incidence rate of SAEs
was 1.8% in the vitamin D3 group and 3.6% in the placebo
group (Supplemental Table 2C). All of the 3 SAEs (2 instances
of appendicitis and 1 instance of cholecystitis) were assessed
as not related in terms of causal relationship to the investi-
gational product. In the analysis of laboratory tests, vital signs,
physical examination, and ECG, several items showed statis-
tically significant differences between baseline and week 24
results, all of which, were changes within clinically normal
ranges and were not clinically significant. In addition, no
Fig. 3. Proportion of subjects whose 25(OH)D levels increase to 20 or 30 ng/mL or higher during the 12-week treatment period. 25(OH)D, 25-hydroxyvitamin D.
Table 2
Proportion of subjects whose 25(OH)D concentrations increased 30 or 20 ng/mL during the 24-week treatment period.
Serum 25(OH)D concentrations 30 ng/mL Serum 25(OH)D concentrations 20 ng/mL
Vitamin D3 group
(N ¼ 56)
Placebo group
(N ¼ 28)
p Vitamin D3 group
(N ¼ 56)
Placebo group
(N ¼ 28)
p
n (%) n (%) n (%) n (%)
Within week 4 16 (28.6) 0 (0.0) 0.0017a 44 (78.6) 0 (0.0) <0.0001a
Within week 6 19 (33.9) 0 (0.0) 0.0005a 51 (91.1) 1 (3.6) <0.0001a
Within week 8 25 (44.6) 1 (3.6) 0.0001a 52 (92.9) 3 (10.7) <0.0001a
Within week 12 26 (46.4) 1 (3.6) <0.0001a 52 (92.9) 3 (10.7) <0.0001a
Within week 18 40 (71.4) 1 (3.6) <0.0001a 55 (98.2) 3 (10.7) <0.0001a
Within week 24 41 (73.2) 1 (3.6) <0.0001a 56 (100.0) 4 (14.3) <0.0001a
25(OH)D, 25-hydroxyvitamin D.
a Pearson's chi-square test.
Fig. 4. Mean serum 25(OH)D levels over the 24-week treatment period. 25(OH)D, 25-hydroxyvitamin D.
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Table 3
Pharmacokinetic parameters including DCmax, Tmax, and AUC12weeks after a
single injection of the vitamin D3 200,000 IU.
Pharmacokinetic parameters
(n ¼ 56)
Mean ± SD Median Minimum,
maximum
DCmax (ng/mL) 21.2 ± 7.2 20.4 7.9, 41.3
Tmax (day) 55.2 ± 25.5 55.0 13.0, 102.0
AUC12weeks (ng$day/mL) 1064.7 ± 435.5 1096.7 197.5, 2136.0
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to 60 ng/mL at any time point up to week 24 after the
investigational product injection.
4. Discussion
The present study shows that a single injection of vitamin D3
200,000 IU was able to increase serum 25(OH)D concentrations
to30 ng/mL in almost half of subjects, and20 ng/mL in over
90% of the subjects within 12 weeks. A repeat injection of
vitamin D3 200,000 IU was able to increase serum 25(OH)D
concentrations to30ng/mL inmore than 70%of subjects and to
20 ng/mL in all subjects within 24 weeks. These results indi-
cate that intramuscular injection of vitamin D3 200,000 IU is an
effective way to increase serum 25(OH) concentrations and
achieve an adequate or sufficient vitamin D status in Korean
adults with vitamin D deficiency defined as serum 25(OH)D
concentration <20 ng/mL. However, some subjects (28.57%)
still could not achieve serum 25(OH)D concentrations 30 ng/
mL by week 24 after a repeat injection, which means that mul-
tiple injections (2 times) of high-dose vitaminD3 formore than
24 weeks are needed to achieve sufficient vitamin D level in
many patients with vitamin D deficiency. Nonetheless, all sub-
jects achieved their serum 25(OH)D concentrations above 20 ng/
mL within week 24. Although serum 25(OH)D concentration
30 ng/mL is generally accepted as the optimal level for skeletal
health, especially in those with established osteoporosis [15], a
number of researchers andorganizations support a serum25(OH)
D concentration of 20 ng/mL as an enough level for general
population [14,16]. Likewise, both the Korean Society of Oste-
oporosis and the Korean Society for Bone andMineral Research
also recommend a serum 25(OH)D concentration20 ng/mL as
an appropriate level for prevention of osteoporosis in general
population of Korea [17].
There has been no randomized controlled trial (RCT) that
investigated the efficacy of vitamin D replacement in terms of
fracture or fall in Korean population. Only a few prospective
RCTs including current one have assessed the efficacy of
vitamin D replacement in Korean population in terms of
change in serum 25(OH)D concentration. Two previous RCTs
investigated the efficacies of orally administered vitamin D
combined with bisphosphonates [18,19]. One RCT compared
the efficacy of once weekly alendronate 70 mg plus vitamin D3
5600 IU with alendronate 70 mg without additional vitamin D
in Korean osteoporotic women whose mean serum 25(OH)D
concentration was 18.71 ± 6.50 ng/mL at baseline [18]. Once
weekly alendronate plus vitamin D3 5600 IU was able to in-
crease the serum 25(OH)D levels to 15 ng/mL or greater inover 98% of subjects after 16-week treatment. The mean
serum 25(OH)D levels after 8 and 16 weeks were 28.35 ± 5.03
and 30.08 ± 5.87 ng/mL, respectively, in the once weekly
alendronate plus vitamin D3 5600 IU group compared with
17.99 ± 5.47 and 17.14 ± 6.04 ng/mL in the alendronate alone
group, which makes the mean differences in serum 25(OH)D
levels between two groups as 10.41 and 12.94 ng/mL at week
8 and 16, respectively. Another RCT also compared the effi-
cacy of a once monthly ibandronate 150 mg plus vitamin D3
24,000 IU with a once monthly ibandronate 150 mg without
additional vitamin D in postmenopausal women whose mean
serum 25(OH)D concentration was about 21 ng/mL at baseline
[19]. This study showed that the proportion of patients with a
25(OH)D level >20 ng/mL increased from 46.9% to 63.5% in
the ibandronate plus vitamin D3 24,000 IU group but
decreased from 40.0% to 26.3% in the ibandronate alone
group after 16-week treatment. The mean serum 25(OH)D
levels after 8 and 16 weeks were 24.8 ± 9.0 and 25.3 ± 9.9 ng/
mL, respectively, in the once monthly ibandronate plus
vitamin D3 24,000 IU group compared with 18.3 ± 7.4 and
17.4 ± 9.2 ng/mL in the ibandronate alone group, which made
the mean differences in serum 25(OH)D levels between two
groups as 6.5 and 7.9 ng/mL at week 8 and 16, respectively.
Therefore, although it is difficult to directly compare the ef-
ficacy of vitamin D replacement between these previous RCTs
and our study, intramuscular injection of vitamin D3 200,000
IU seems to be a better strategy to improve serum 25(OH)D
concentration considering that the mean differences in serum
25(OH)D levels between vitamin D3 and placebo group were
14.1, 13.9, 21.0, and 20.3 ng/mL at week 8, 12, 18, and 24,
respectively, in the present study.
As an exploratory endpoint in the present study, mean
serum PTH concentrations showed a significant decrease over
24 weeks after investigational product injection in the vitamin
D3 group, but not in the placebo group, which made statis-
tically significant inter-group difference at week 8, 18, and
24. Because high PTH may affect bone metabolism nega-
tively by increasing bone turnover, it is expected that
decreased PTH level after vitamin D3 injection can be
beneficial for skeletal health. Results from the subgroup an-
alyses in the present study showed that mean change in serum
25(OH)D concentrations at week 4, 6, 8, and 12 after the
vitamin D3 injection from baseline was an increase of
16.6 ng/mL, 17.2 ng/mL, 17.5 ng/mL, and 14.8 ng/mL,
respectively, among the subjects with serum 25(OH)D con-
centrations <10 ng/mL at screening and an increase of
13.2 ng/mL, 14.9 ng/mL, 13.4 ng/mL, and 10.9 ng/mL,
respectively, among the subjects with serum 25(OH)D con-
centrations 10e20 ng/mL at screening. These results indicate
a greater increase of serum 25(OH)D concentrations in the
subgroup with serum 25(OH)D concentrations <10 ng/mL
prior to administration of vitamin D3 than in the 10e20 ng/
mL subgroup, which suggests that vitamin D3 injection may
increase serum 25(OH)D concentrations more effectively in
those with more severe vitamin D deficiency.
With regards to the safety, replacement of high-dose
vitamin D, especially with calcium can cause toxicity
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Women's Health Initiative study also showed an increased
incidence of urinary tract stones in those who were taking
vitamin D and calcium supplements [20], although it is un-
likely that treating vitamin D deficiency with vitamin D alone
would increase the risk of urinary tract stones. Recently, some
observational cohort studies have shown a reverse-J-shaped
curve for the relationship between serum 25(OH)D concen-
tration and all-cause or cardiovascular mortality with
increased risk at both lower and higher serum levels of
25(OH)D [21,22]. In the present study, hypercalcemia
occurred in only 1.8% (1/56 subjects, 1 event) in the vitamin
D3 group, which was found to be mild. Hypercalciuria
occurred in 5.4% (3/56 subjects, 3 events) in the vitamin D3
group and 7.1% (2/28 subjects, 3 events) in the placebo group
without significant difference. In addition, no subject showed
an increase in serum 25(OH)D concentrations to 60 ng/mL
at any time point up to week 24 after the investigational
product injection. Therefore, there is little chance of excessive
increase of vitamin D level after intramuscular injection of
vitamin D3 200,000 IU.
In conclusion, intramuscular injection of vitamin D3
200,000 IU in adults with vitamin D deficiency was demon-
strated to be superior to placebo in terms of the proportions of
subjects with achieved serum 25(OH)D concentrations 30 or
20 ng/mL. In addition, change in serum 25(OH)D concen-
trations over 24 weeks after vitamin D3 injection also indicated
a statistically significant increase in the vitamin D3 group
compared with the placebo group, and change in serum PTH
concentrations showed a statistically significant decrease bothAppendix Table 1
Proportion of subjects whose 25(OH)D concentrations increased 30 or 20 ng/mL
analyses).
A. Serum 25(OH)D concentrations 30 ng/mL.
Repeat injection administered
Vitamin D3 group (N¼49) Placebo group (N¼27) p
n (%) n (%)
Within week 4 13 (26.5) 0 (0.0) 0
Within week 6 16 (32.7) 0 (0.0) 0
Within week 8 20 (40.8) 1 (3.7) 0
Within week 12 20 (40.8) 1 (3.7) 0
Within week 18 34 (69.4) 1 (3.7) <
Within week 24 35 (71.4) 1 (3.7) <
B. Serum 25(OH)D concentrations 20 ng/mL.
Repeat injection administered
Vitamin D3 group (N¼49) Placebo group (N¼27) p
n (%) n (%)
Within week 4 39 (79.6) 0 (0.0) <
Within week 6 44 (89.8) 1 (3.7) <
Within week 8 45 (91.8) 3 (11.1) <
Within week 12 45 (91.8) 3 (11.1) <
Within week 18 48 (98.0) 3 (11.1) <
Within week 24 49 (100.0) 4 (14.8) <
25(OH)D, 25-hydroxyvitamin D.
a Pearson's chi-square test.
b Fisher's exact test.
c Repeat injection was not administered in 1 subject in vitamin D3 group and 1within the vitamin D3 group and between the vitamin D3 and
placebo groups. Therefore, mega-dose intramuscular injection
of vitamin D3 200,000 IU is considered to be an effective and
safe strategy to improve vitamin D level in Korean adults at the
age of 19 and < 65 with vitamin D deficiency.
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Appendixduring the 24-week treatment period depending on repeat injection (subgroup
Repeat injection not administeredc
Vitamin D3 group (N¼7) Placebo group (N¼1) p
n (%) n (%)
.0028b 3 (42.9) 0 (0.0) 1.0000b
.0008a 3 (42.9) 0 (0.0) 1.0000b
.0005a 5 (71.4) 0 (0.0) 0.3750b
.0005a 6 (85.7) 0 (0.0) 0.2500b
0.0001a 6 (85.7) 0 (0.0) 0.2500b
0.0001a 6 (85.7) 0 (0.0) 0.2500b
Repeat injection not administered
Vitamin D3 group (N¼7) Placebo group (N¼1) p
n (%) n (%)
0.0001a 5 (71.4) 0 (0.0) 0.3750b
0.0001a 7 (100.0) 0 (0.0) 0.1250b
0.0001a 7 (100.0) 0 (0.0) 0.1250b
0.0001a 7 (100.0) 0 (0.0) 0.1250b
0.0001a 7 (100.0) 0 (0.0) 0.1250b
0.0001a 7 (100.0) 0 (0.0) 0.1250b
subject in placebo group due to dropout.
Appendix Table 2
Safety assessment.
A. Adverse events.
Category Test group (N¼56) Comparator group (N¼28)
n (%) [event] n (%) [event]
Infections and infestations 18 (32.1) [23] 10 (35.7) [11]
Gastrointestinal disorders 6 (10.7) [7] 4 (14.3) [5]
Nervous system disorders 4 (7.1) [4] 3 (10.7) [3]
Renal and urinary disorders 4 (7.1) [5] 2 (7.1) [3]
General disorders and administration site conditions 5 (8.9) [7] 0 (0.0) [0]
Injury, poisoning and procedural complications 2 (3.6) [2] 3 (10.7) [3]
Investigations 2 (3.6) [3] 2 (7.1) [2]
Musculoskeletal and connective tissue disorders 2 (3.6) [2] 0 (0.0) [0]
Reproductive system and breast disorders 1 (1.8) [1] 1 (3.6) [1]
Respiratory, thoracic and mediastinal disorders 1 (1.8) [1] 1 (3.6) [1]
Skin and subcutaneous tissue disorders 1 (1.8) [1] 1 (3.6) [1]
Vascular disorders 2 (3.6) [2] 0 (0.0) [0]
Blood and lymphatic system disorders 1 (1.8) [1] 0 (0.0) [0]
Cardiac disorders 0 (0.0) [0] 1 (3.6) [1]
Ear and labyrinth disorders 0 (0.0) [0] 1 (3.6) [1]
Eye disorders 1 (1.8) [1] 0 (0.0) [0]
Hepatobiliary disorders 1 (1.8) [1] 0 (0.0) [0]
Metabolism and nutrition disorders 1 (1.8) [1] 0 (0.0) [0]
Total 32 (57.1) [62] 19 (67.9) [32]
B. Adverse drug reactions.
Category Test group (N¼56) Comparator group (N¼28)
n (%) [event] n (%) [event]
Renal and urinary disorders 3 (5.4) [3] 2 (7.1) [3]
Hypercalciuria 3 (5.4) [3] 2 (7.1) [3]
General disorders and administration site conditions 3 (5.4) [4] 0 (0.0) [0]
Injection site granuloma 1 (1.8) [1] 0 (0.0) [0]
Injection site nodule 1 (1.8) [1] 0 (0.0) [0]
Injection site reaction 1 (1.8) [1] 0 (0.0) [0]
Injection site urticaria 1 (1.8) [1] 0 (0.0) [0]
Infections and infestations 1 (1.8) [1] 0 (0.0) [0]
Injection site infection 1 (1.8) [1] 0 (0.0) [0]
Metabolism and nutrition disorders 1 (1.8) [1] 0 (0.0) [0]
Hypercalcemia 1 (1.8) [1] 0 (0.0) [0]
Total 6 (10.7) [9] 2 (7.1) [3]
C. Serious adverse events.
Category Test group (N¼56) Comparator group (N¼28)
n (%) [event] n (%) [event]
Infections and infestations 1 (1.8) [1] 1 (3.6) [1]
Appendicitis 1 (1.8) [1] 1 (3.6) [1]
Hepatobiliary disorders 1 (1.8) [1] 0 (0.00) [0]
Cholecystitis 1 (1.8) [1] 0 (0.00) [0]
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